GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » NonCurrent Deferred Liabilities

Akeso (HKSE:09926) NonCurrent Deferred Liabilities : HK$0 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Akeso NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Akeso's non-current deferred liabilities for the quarter that ended in Dec. 2023 was HK$0 Mil.

Akeso NonCurrent Deferred Liabilities Historical Data

The historical data trend for Akeso's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso NonCurrent Deferred Liabilities Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial - - - - -

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Akeso NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Akeso's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Akeso (HKSE:09926) Business Description

Industry
Traded in Other Exchanges
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines